06/23/18 Toll-like receptor 4 expression and functional signaling in human and murine B-cell lymphomas is strongly associated with response to treatment with the synthetic TLR4 agonist G100. AACR International Meeting Advances in Malignant Lymphoma. Abstract #158. View Poster.
04/18/18 Component-specific qPCR assays for characterization and identity testing of multigenome ZVex®, a dendritic cell-targeting lentiviral vector platform. American Association for Cancer Research (AACR) 2018 Annual Meeting. Abstract #5919. View poster.
01/25/18 Effect of intratumoral (IT) injection of the toll-like receptor 4 (TLR4) agonist G100 on a clinical response and CD4 T-cell response locally and systemically. 2018 ASCO-SITC Clinical Immuno-Oncology Symposium. Abstract #71. View Poster.
01/23/18 Humoral and cell-mediated immune responses to H5N1 plant-made virus-like particle vaccine are differentially impacted by alum and GLA-SE adjuvants in a Phase 2 clinical trial. npj Vaccines. January 2018. View Publication.
01/12/18 TLR4 Agonist Glucopyranosyl Lipid A (GLA) Induces T-regulatory Cells and Suppresses Th2 Cytokines in PBMC from Cashew-Allergic Donors. Mechanisms, Prevention of, and Emerging Therapies for Food Allergy Conference 2017. View Poster.
12/10/17 Intratumoral G100 Induces Systemic Immunity and Abscopal Tumor Regression in Patients with Follicular Lymphoma: Results of a Phase 1/2 Study Examining G100 Alone and in Combination with Pembrolizumab. 59th American Society of Hematology (ASH) Annual meeting. Abstract # 2771. View Poster.
11/10/17 Anti-NY-ESO-1 immune response and survival benefit after LV305 therapy in patients with advanced sarcoma and other solid tumors. Society for Immunotherapy of Cancer 2017 Annual Meeting. Poster #P109. View Poster.
11/10/17 G100 and ZVex®-based combination immunotherapy induces near complete regression of established glioma tumors in mice. Society for Immunotherapy of Cancer 2017 Annual Meeting.Poster #P256. View Poster.
11/10/17 Transduction of MAGE-A1, A3, A4, A10 and IL-12 by ZVex®, a dendritic cell targeting platform induces robust multi-antigen T-cell immune responses without antigenic interference or immunodominance. Society for Immunotherapy of Cancer 2017 Annual Meeting. Poster #P127. View Poster.
11/10/17 Single dose of intratumoral expression of IL12 using the ZVex® dendritic cell-targeting lentiviral vector exerts potent anti-tumor effects via induction of multiple immune effectors. Society for Immunotherapy of Cancer 2017 Annual Meeting. Poster #P401. View Poster.
